Feasibility and limitations of comorbidity measurement in patients undergoing radical prostatectomy

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Michael Froehner - , University Hospital Carl Gustav Carus Dresden, Department of Urology (Author)
  • Rainer Koch - , University Hospital Carl Gustav Carus Dresden, Institute for Medical Informatics and Biometry (Author)
  • Rainer J. Litz - , University Hospital Carl Gustav Carus Dresden, Department of Anesthesiology and Intensive Care Medicine (Author)
  • Sven Oehlschlaeger - , University Hospital Carl Gustav Carus Dresden, Department of Urology (Author)
  • Oliver W. Hakenberg - , University Hospital Carl Gustav Carus Dresden, Department of Urology (Author)
  • Manfred P. Wirth - , University Hospital Carl Gustav Carus Dresden, Department of Urology (Author)

Abstract

To compare different comorbidity classifications as predictors of survival after radical prostatectomy (RPE). 444 consecutive RPE patients (mean follow-up 6.9 years) were stratified according to age, Charlson score, American Society of Anesthesiologists Physical Status classification (ASA), New York Heart Association classification of cardiac insufficiency, classification of angina pectoris of the Canadian Cardiovascular Society and a combination of both cardiac risk scores. Comorbid and overall mortality were the study endpoints. Mantel-Haenszel hazard ratios, p values and 8-year survival probabilities were used for comparison. A modified Charlson score was created by a restriction to the five individual conditions significantly associated with comorbid mortality. When three strata (low, intermediate, high risk) were used, all stratifications displayed dose-response patterns and reached statistical significance as predictors of survival at least for the high-risk group. Only the ASA classification, however, discriminated three significantly different risk groups. Only the modified (restricted) Charlson score reached statistical significance as predictor of comorbid mortality in the age group of 70 or more years. Although all investigated comorbidity classifications had some prognostic relevance in patients selected for RPE, their clinical applicability appears to be limited beyond the 70th year of life. The results of this study might, nevertheless, assist the treatment decision in patients with low-risk tumors eligible for modern watchful waiting strategies who mainly belong to the age group between 60-69 years where comorbidity seems to be of distinct prognostic value.

Details

Original languageEnglish
Pages (from-to)190-195
Number of pages6
JournalEuropean urology
Volume47
Issue number2
Publication statusPublished - Feb 2005
Peer-reviewedYes

External IDs

PubMed 15661413

Keywords

Sustainable Development Goals

ASJC Scopus subject areas

Keywords

  • Age, ASA classification, Charlson score, Comorbidity, Heart disease, Preoperative cardiopulmonary risk assessment, Prognostic factors, Prostate cancer, Radical prostatectomy, Survival